Skip to main content
U.S. Department of Energy
Office of Scientific and Technical Information

Palladium-109 labeled anti-melanoma monoclonal antibodies

Patent ·
OSTI ID:1176622
Palladium-109, a beta-emitting radionuclide, when chelated to anti-melanoma monoclonal antibody demonstrates high uptake in melanoma and thus is useful for tumor therapy.
Research Organization:
Brookhaven National Laboratory (BNL), Upton, NY (United States)
Sponsoring Organization:
USDOE
DOE Contract Number:
AC02-76CH00016
Assignee:
The United States of America as represented by the United States Department of Energy (Washington, DC)
Patent Number(s):
H000819
Application Number:
06/605439
OSTI ID:
1176622
Country of Publication:
United States
Language:
English

References (8)

Tumor Imaging with Radioactive Metal Chelates Conjugated to Monoclonal Antibodies journal March 1982
The preparation and labeling of DTPA-coupled albumin journal May 1982
Distribution and molecular characterization of a cell-surface and a cytoplasmic antigen detectable in human melanoma cells with monoclonal antibodies journal September 1981
Covalent attachment of chelating groups to macromolecules journal July 1977
Selective binding of metal ions to macromolecules using bifunctional analogs of EDTA journal December 1974
Bumetanide inhibition of NaCl transport byNecturus gallbladder journal June 1983
Covalent attachment of metal chelates to proteins:the stability in vivo and in vitro of the conjugate of albumin with a chelate of 111indium. journal November 1976
Errata journal January 1983

Similar Records

Palladium-109 labeled anti-melanoma monoclonal antibodies
Patent · Sun Dec 31 23:00:00 EST 1989 · OSTI ID:875259

Palladium-109 labeled anti-melanoma monoclonal antibodies
Patent · Mon Apr 30 00:00:00 EDT 1984 · OSTI ID:6110979

Potential of palladium-109-labeled antimelanoma monoclonal antibody for tumor therapy
Journal Article · Sun Jul 01 00:00:00 EDT 1984 · J. Nucl. Med.; (United States) · OSTI ID:6668913